Loading
A phase 2 trial of Ruvidar® (TLD-1433) bladder infusion and PDT in bladder & urothelial cancer, run by Theralase® Technologies Inc., now recruiting.
Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients is a phase 2 interventional study registered as NCT03945162 by Theralase® Technologies Inc., with 90 participants planned, started 2019-08-30 and due to reach its primary completion in 2026-12. Interventions recorded: Ruvidar® (TLD-1433) bladder infusion and PDT.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer and the tag pipeline.